Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS

Anatolia Tani has a liquidity ratio of 2.82 (current ratio) and a debt-to-equity of 0.17, indicating a relatively conservative capital structure. However, the company reported negative free cash flow of -600.98 million TRY and capital expenditures of -435.99 million TRY, suggesting significant reinvestment in operations. The negative net income of -312.73 million TRY contrasts with positive operating cash flow of 186.55 million TRY, highlighting non-cash expenses or working capital adjustments. Profitability metrics are weak, with a return on equity of -18% and return on assets of -13.23%, both below the industry median for biotechnology firms. The company’s operating margin is -2.6% (operating income of -19.21 million TRY on revenue of 739.63 million TRY), indicating challenges in cost control or pricing power. The company operates as a single-segment entity, with all revenue derived from its core molecular diagnostics business in Turkey. Geographic concentration is high, with no disclosed international revenue, exposing it to local regulatory and economic risks. Revenue growth is not disclosed, but the company’s operating cash flow of 186.55 million TRY suggests some operational resilience. However, the negative net income and free cash flow indicate ongoing financial stress. The company’s long-term debt of 295.85 million TRY and total liabilities of 625.15 million TRY suggest limited capacity for further debt financing. Risk factors include medium liquidity risk due to negative free cash flow and a key flag of net cash being negative after subtracting total debt. Dilution risk is low, with no difference between basic and diluted shares outstanding. However, the company’s negative net income and high reinvestment needs may pressure future earnings. Recent filings highlight the company’s focus on reducing foreign dependency in molecular diagnostics and expanding its global market presence. No recent earnings call transcripts or major regulatory filings were disclosed in the input data.